Can a second TKI stop work? new trial tests nilotinib for CML patients
NCT ID NCT02917720
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 34 times
Summary
This study looks at whether the drug nilotinib can help people with chronic myeloid leukemia (CML) stay in remission after stopping their usual treatment for a second or third time. About 75 adults who previously tried and failed to stop TKI therapy will take nilotinib for at least two years, then try stopping again. The goal is to see how long they can remain cancer-free without restarting medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC, locatie VUmc
Amsterdam, 1081 HV, Netherlands
-
Kliniken Ostalb, Stauferklinikum Schwäbisch Gmünd
Mutlangen, 73557, Germany
-
Klinikum Bayreuth
Bayreuth, 95445, Germany
-
Klinikum Chemnitz
Chemnitz, 09113, Germany
-
Klinikum der Philipps-Universität
Marburg, 35033, Germany
-
Klinikum rechts der Isar
München, Bavaria, 81675, Germany
-
Medizinische Hochschule Hannover
Hannover, North Rhine-Westphalia, 30625, Germany
-
Onkologische Schwerpunktpraxis
Esslingen am Neckar, 73728, Germany
-
Schwarzwald-Baar Klinikum
Villingen-Schwenningen, 78052, Germany
-
Schwerpunktpraxis Onkologie
Heilbronn, 74072, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, 79108, Germany
-
Universitätsklinikum Halle (Saale)
Halle, Germany
-
Universitätsklinikum Rostock
Rostock, 18057, Germany
-
Universitätsklinikum der RWTH
Aachen, 52074, Germany
-
Universitätsmedizin Mannheim
Mannheim, Baden-Wurttemberg, 68167, Germany
Conditions
Explore the condition pages connected to this study.